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Background: The recent emergence of Clostridium difficile infections has included this condition among top
nosocomial infections, due to its incidence, complications and important fatality, as well as to significant economic
costs.
Methods: A prospective surveillance study of Clostridium difficile enterocolitis cases was performed in “Victor Babeş”
Infectious Diseases Hospital in Timişoara (Romania) between 01.01.2013 - 30.06.2014, to estimate the incidence and
to investigate the risk factors for unfavourable outcome and relapse. Dichotomous variables were compared by the
chi-square test or Fisher exact test and the Mann–Whitney U test was used for continuous variables. Risk factors for
unfavourable outcome/recurrence were investigated by logistic regression.
Results: 210 patients who experienced 219 episodes of infection with Clostridium difficile were identified, which gives
an incidence per hospital of 20.57/15.70 to 1,000 discharged patients in 2013/2014 or 17.73/14.04 to 10,000 patient-
days. In 162 patients (77.14%) the evolution was favourable while in 48 (22.86%) the outcome was unfavourable. In 42
patients (20.00%) recurrence of symptoms was identified. The multivariate analysis by logistic regression identified the
ATLAS score (OR = 4.97, 95% CI = 2.12 to 11.66, p <0.001), age (OR = 1.12, 95% CI = 1.00 to 1.25, p = 0.046), and the
number of antibiotics after episode onset (OR = 2.692, 95% CI = 1.01 to 7.17, p = 0.047) as predictors of an unfavourable
evolution, while the number of hospitalization days (OR = 1.10, 95% CI = 1.03 to 1.16, p = 0.0015) was associated with
recurrence of symptoms.
Conclusions: The high incidence identified in our study is explained by the endemic character of these infections in
some hospitals in Timişoara, released in late 2012, and the fact that “Victor Babeş” Hospital is the only one in our area
that provides treatment in all suspected or confirmed cases of this condition requiring hospitalization. The study
identified the ATLAS score, age, and the number of antibiotics after episode onset as predictors of unfavourable
evolution, while the number of days of hospitalization was associated with the recurrence of symptoms.
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The emergence of Clostridium difficile-associated dis-
ease (CDAD) in recent years has imposed this condition
among nosocomial infections, by incidence, significant
complications, and fatality, as well as significant eco-
nomic costs.
Surveillance results on the point prevalence of nosoco-
mial infections and their relation of causality with the
use of antibiotics in European hospitals, in studies con-
ducted by the European Centre for Disease Prevention
and Control showed that 5.4% healthcare-associated in-
fections with documented bacterial aetiology were deter-
mined by Clostridium difficile (CD) [1].
According to a 2013 study on the point prevalence of
healthcare associated infections in long-term care insti-
tutions in Europe, CD was identified as causative agent
of gastrointestinal infections in 12.1% of cases in Italy,
18.2% in Ireland and 20.6% in Germany [2].
In Barcelona hospitals, in 2009, the incidence varied
between 0 and 5.97 to 1,000 discharged patients and,
according to a study from 2011, the annual incidence in
Spain is estimated at 1.71 cases per 1,000 admitted pa-
tients [3,4].
An evaluation performed by the European Centre for
Disease Prevention and Control - European Society of
Clinical Microbiology and Infectious Diseases estimates
the direct cost of care in Europe at 3,700 million euros
(updated data for 2013) and 7,000-7,500 euros/hospital-
ized patient in Italy, Germany and Britain [5]. In Romania,
the increase of the CDAD incidence started in 2011, when
these cases started to be investigated for CD by appropri-
ate bacteriological tests, and in 2013, 1,237 cases were re-
ported nationwide, with a significantly higher proportion
of the 027 ribotype, a strain with increased transmissibil-
ity rates/sporogenesis, increased production of A and B
specific toxins and additional binary toxin production [5].
The interest aroused by the frequency of this path-
ology (not identified in our region until 2012), is all the
more justified since, after its identification by Holl and
O'Tooll in 1935, for 43 years, this bacterium was only
labelled as saprophytic, included in the normal resident
flora of the digestive tract. Clinical observations after
1978, but especially in recent years, bring evidence of
certain changes in the clinical course and epidemiology
of CD infections. An increase in the number of severe
forms of illness is recorded, more frequently affecting
patients over 65 years, together with higher numbers of
community acquired cases and of individuals previously
considered at minor risk who develop the disease.
In this context, the aims of our study were to esti-
mate the incidence and to clarify some epidemio-
logical aspects regarding the CDAD in an Infectious
Diseases Hospital providing healthcare for the popula-




We conducted a prospective surveillance study, in-
cluding all patients diagnosed with CDAD, hospital-
ized between 01.01.2013 - 30.06.2014 at the Clinical
Hospital of Infectious Diseases and Pneumophtisiology
“Victor Babeş” Timişoara, an hospital with 120 beds,
with 7,194 discharged patients in 2013/3,949 in 2014
and 83,484 patient-days in 2013/44,146 in 2014.
We only included laboratory confirmed cases in patients
aged 18 or older, regardless of gender, personal history
and probable infection source i.e. nosocomial or commu-
nity acquired. After being discharged, the patients were
surveyed for three months in order to detect possible
recurrence and unfavourable evolutions. The database in-
cluded only the first episode of CDAD for each patient.
We collected demographic data, the total number of
days of hospitalization for CDAD, the presence of vari-
ous comorbidities (malignancy, diabetes, chronic renal
failure, cardiac, pulmonary, mild/moderate/severe liver
pathology, or peripheral vascular, cerebrovascular, hae-
matological diseases, dementia, gastro-duodenal ulcer,
presence of concomitant infections); possible causes of
immunosuppression during the last 2 months prior to the
onset of CDAD (chemotherapy, radiotherapy, corticoste-
roids, chronic dialysis, surgery - including the type of
intervention); other risk factors (inflammatory bowel dis-
ease, colorectal cancer, previous exposure to antimicrobial
agents, enteral/parenteral nutrition), and the possible un-
favourable evolution (continuing the administration of
drugs which slow down intestinal motility, proton pump
inhibitors, other antacids, antibiotics - other than those
for CD, specifying the number of days and number of
antibiotics received); clinical data (serum albumin, blood
leukocyte count, body temperature) with the calculation
of the ATLAS Score, recording progress and treatment
received.
The case definition for CDAD included the presence
of the diarrheal syndrome (≥3 stools per day) or toxic
megacolon. The aetiology was confirmed by the VIDAS®
C. difficile Toxin A & B (bioMérieux) test, an ELFA
(Enzyme-Linked Fluorescent Assay) that detects toxins
A and B in fresh stool samples. In patients with positive
symptoms but negative tests for toxins, the test was
repeated after 48-72 h.
The “Unfavourable outcome” was defined as death
within 30 days after onset of the episode (in hospital/at
home) or complications requiring transfer to a surgical
ward. The recurrence of symptoms within less than
8 weeks was classified as relapse and after this limit as
recidivation.
Table 1 Demographic characteristics and comorbidity of
the sample included in the study (N = 210 cases)
The characteristic Identified value
Demographic characteristics
Median age [years (IQR)] 68 (57–77)
Female gender [n (%)] 110 (52.38)
Urban area [n (%)] 146 (69.52)
County of residence Timiş [n (%)] 181 (86.20)
County of residence Caraş-Severin [n (%)] 10 (4.76)
County of residence Hunedoara [n (%)] 5 (2.38)
County of residence Arad [n (%)] 1 (0.47)
Other counties [n (%)] 13 (6.19)
Clinical and evolutive features
Nosocomial infection with CD [n (%)] 204 (97.14)
Community infection with CD [n (%)] 6 (2.86)
Patients cured [n (%)] 162 (77.14)
Patients deceased in the hospital [n (%)] 40 (19.05)
Patients deceased later, at home [n (%)] 5 (2.38)
Transferred patients [n (%)] 3 (1.43)
Relapses [n (%)] 42 (20)
Median of the no.of days of hospitalization
for CDAD [days (IQR)]
10 (7–13)
Median no. of days between the first CDAD
episode and the recurrence of symptoms
[days (IQR)]*
14 (7–21)
Median no. of leucocytes [cells/μl (IQR)] 10040 (7210–14800)
Leukocytosis ≥ 16.000 cells/μl [n (%)] 44 (20.95)
Hypoalbuminemia <3,5 g/dL [n (%)] 166 (79.05)
Fever > 37.5°C [n (%)] 51 (24.49)
Median ATLAS score (IQR) 3 (2–4)
Mild clinical form [n (%)] 7 (3.33)
Moderate clinical form [n (%)] 153 (72.86)
Sever clinical form [n (%)] 50 (23.81)
Comorbidities
Median Charlson comorbidity index score (IQR) 2.5 (1–4)
Median Charlson comorbidity Index score adjusted
for age (IQR)
5 (1–5)
Malignancy [n (%)] 44 (20.95)
Colorectal cancer [n (%)] 5 (2.38)
Diabetes mellitus [n (%)] 48 (22.86)
Renal disease [n (%)] 47 (22.38)
Chronic renal failure [n (%)] 35 (16.67)
Chronic heart disease [n (%)] 111 (52.86)
Peripheral vascular disease [n (%)] 40 (19.05)
Dementia [n (%)] 10 (4.76)
Cerebrovascular disease [n (%)] 55 (26.19)
Chronic pulmonary pathology [n (%)] 38 (18.09)
Table 1 Demographic characteristics and comorbidity of
the sample included in the study (N = 210 cases)
(Continued)
Moderate/severe liver pathology [n (%)] 26 (12.38)
Ulcerous disease [n (%)] 23 (10.95)
Inflammatory bowel disease [n (%)] 5 (2.38)
Haematological pathology [n (%)] 6 (2.86)
Concomitant infections [n (%)] 59 (28.09)
Risk factors for CDAD in the past 2 months
Chemotherapy [n (%)] 14 (6.67)
Radiotherapy [n (%)] 7 (3.33)
Corticotherapy [n (%)] 15 (7.14)
Dialysis [n (%)] 7 (3.33)
Surgery [n (%)] 97 (46.19)
Gastro-intestinal/abdominal surgery [n (%)] 43 (20.48)
Enteral feeding [n (%)] 4 (1.90)
Parenteral feeding [n (%)] 22 (10.48)
Prior antibiotic treatment [n (%)] 145 (69.05)
Intestinal motility inhibitors after CDAD onset
[n (%)]
20 (9.52)
Proton pump inhibitors after CDAD onset [n (%)] 22 (10.48)
Other antacids after CDAD onset [n (%)] 65 (30.95)
Antibiotic use after CDAD diagnosis (other than
for CDAD) [n (%)]
32 (15.24)
Median no. of days of antibiotherapy after onset
of episode (other than the treatment for CDAD)
[days (IQR)]
0 (0–0)
Median no. of antibiotics after onset of episode
(other than the treatment for CDAD [no. (IQR)]
0 (0–0)
Treatment for CDAD
Metronidazole [n (%)] 42 (20)
Vancomycin [n (%)] 58 (27.62)
Vancomycin + Metronidazole [n (%)] 99 (47.14)
Rifaximin - α (alone or in combination) [n (%)] 9 (4.28)
Death before initiating the therapy [n (%)] 2 (0.95)
*Calculated for the subsample of relapse (N = 42).
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the “Victor Babeş” Hospital for Infectious Diseases and
Pneumophtisiology Timişoara and the informed consent
was obtained from all patients included. Throughout the
study, the patients received standard treatments and
were not subjected to any further clinical intervention or
investigation.
Statistical analysis
The database was processed using the SPSS software
version 10.0. Continuous numeric variables were charac-
terized by median and range of quartile (IQR) and the
category type by value and percentage. Testing data dis-
tribution was performed using the Kolmogorov-Smirnov
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by chi-square test or Fisher exact test and the Mann–
Whitney U test was used for continuous variables. Statis-
tical significance was calculated by two-tailed tests and
significance threshold was set at p values ≤ 0.05. The cor-
relation of the ATLAS Score with the Charlson comorbid-
ity index was obtained using the Spearman coefficient.
Risk factors for unfavourable outcome/recurrence were
investigated by logistic regression. Independent variables
with p ≤0.10 in the univariate analysis were entered into
multivariate sequenced analysis to obtain Odds ratio and
95% confidence interval. To avoid colinearity, 2 options
were used: i - with the inclusion of the multifaceted inde-
pendent variables, but without their constituent variables;
ii - including only simple independent variables. Model
selection was performed depending on the Nagelkerke R2
coefficient and the deviation from the theoretical model,
estimated by the Hosmer and Lemeshow Goodness of fit
test.Results
210 patients who experienced 219 episodes of CDAD were
identified, yielding an incidence per hospital of 20.57/
15.70 to 1,000 discharged patients in 2013/2014 (95% CI
17.2-24.1/12.2-20.3) or 17.73/14.04 to 10,000 patient-days
(95% CI 10.2-30.1/10.3-20.2) (p = 0.070/0.122). The demo-
graphic characteristics and co-morbidities in the study
group (N = 210) are shown in Table 1.
The most affected were patients aged between 70–79
years, followed by those aged 60–69 and 80–89, as
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Figure 1 Distribution of cases by age group and CDAD development.162 patients (77.14%) responded favourably, while 48
(22.86%) had an unfavourable outcome. 145 (69.05%)
had received prior antibiotic therapy, most of them re-
ceived IIIrd generation cephalosporins (31.03%) and fluor-
oquinolones (28.96%), followed by carbapenems (17.93%)
and β-lactam with β-lactamase inhibitor (15.86%). Two
patients (0.95%) died before the introduction of therapy,
but the remaining 208 were treated, 99 (47.14%) with
Metronidazole + Vancomycin, 58 (27.62%) with Vanco-
mycin and 42 (20%) with Metronidazole.
The ATLAS Score - known for its ability to predict
the unfavourable outcome correlated directly, statisti-
cally significant, with the Charlson comorbidity index
(weak correlation) (r = 0.356, p <0.001) and with the age-
adjusted comorbidity index (medium correlation) (r =
0.505, p <0.001). Also, a medium correlation was detected
between the ATLAS score and the evolution of cases (r =
0.57, p <0.001).
The univariate analysis identified several risk factors
for the unfavourable outcome: age, leukocytosis over
16,000 cells/μl, hypoalbuminemia <3.5 g/dL, fever over
37.5°C, chronic lung pathology and moderate/severe
liver pathology, chemotherapy, parenteral nutrition, anti-
biotic therapy continued after the onset of the episode
(other than therapy for CDAD), number of days and
number of antibacterial agents (other than CDAD ther-
apy), the ATLAS score and the Charlson comorbidity
index, simple or age adjusted. (Table 2) Of these, multi-
variate analysis retained the ATLAS score (OR = 4.97,
95% CI = 2.12 to 11.66, p <0.001) in the first model,
while in option ii age it retained (OR = 1.12, 95% CI =
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Table 2 Risk factors for unfavourable outcome of CDAD
Variable Favorable Unfavourable Univariate analysis Multivariate analysis
(N = 162) (N = 48) p OR (95% CI) p OR (95% CI)
Demographic characteristics
Median age [years (IQR)] 67 (57–75) 76 (58–81) 0.007 1.03 (1.00-1.05) 0.046 1.12 (1.00-1.25)
Female gender [n (%)] 86 (53.09) 24 (50) 0.707 0.88 (0.44-1.77)
Urban area [n (%)] 118 (72.84) 28 (58.33) 0,055 1.92 (0.93-3.94)
Clinical and evolutive characteristics
Nosocomial infection with CD [n (%)] 156 (96.30) 48 (100) 0.340 0.00 (0–2.87)
Relapses [n (%)] 30 (18.52) 12 (25) 0.324 1.47 (0.64-3.35)
Median no. of hospitalization days for CDAD
[days (IQR)]
10 (8–13) 4 (2.5-12.5) 0.002 0.88 (0.82-0.95)
Median no. of leukocytes [cells/μl (IQR)] 9565 (7210–32400) 16100 (7120–20135) <0.001 1.00 (1.0001-1.0002)
Leukocytosis ≥ 16000 cells/μl [n (%)] 19 (11.73) 25 (52.08) <0.001 8.18 (3.67-18.43)
Hypoalbuminemia < 3.5 g/dl [n (%)] 119 (73.46) 47 (97.92) <0.001 16.98 (2.70-700.55)
Fever > 37.5°C [n (%)] 21 (12.96) 31 (64.58) <0.001 12.24 (5.45-27.88)
Median ATLAS Score (IQR) 2 (1–3) 5 (4–6) <0.001 2.72 (2.02-3.67) <0.001 4.97 (2.12-11.66)
Mild clinical form [n (%)] 7 (4.32) 0 (0) 0.355 0.00 (0.00-2.33)
Moderate clinical form [n (%)] 150 (92.59) 3 (6.25) <0.001 0.01 (0.00-0.02)
Sever clinical form [n (%)] 5 (3.09) 45 (93.75) <0.001 471 (94.88-2836.91)
Comorbidities
Median Charlson comorbidity index score (IQR) 2 (1–3) 4 (3–5.5) <0.001 1.48 (1.26-1.73)
Median Charlson comorbidity index score
adjusted for age (IQR)
4.5 (2–6) 7 (5.5-8.5) <0.001 1.40 (1.22-1.60)
Malignancy [n (%)] 31 (19.14) 13 (27.08) 0.234 1.57 (0.69-3.52)
Colorectal cancer [n (%)] 5 (3.09) 0 (0) 0.590 0.00 (0.00-3.70)
Diabetes mellitus [n (%)] 35 (21.61) 13 (27.08) 0.427 1.35 (0.60-2.99)
Renal disease [n (%)] 35 (21.61) 12 (25) 0.620 1.21 (0.53-2.72)
Chronic renal failure [n (%)] 23 (14.20) 12 (25) 0.078 2.01 (0.85-4.73)
Chronic heart disease [n (%)] 80 (49.38) 31 (64.58) 0.064 1.87 (0.91-3.85)
Peripheral vascular disease [n (%)] 28 (17.28) 12 (25) 0.231 1.60 (0.69-3.66)
Dementia [n (%)] 7 (4.32) 3 (6.25) 0.699 1.48 (0.24-6.78)
Cerebrovascular disease [n (%)] 37 (22.84) 18 (37.50) 0.042 2.03 (0.96-4.27)
Chronic pulmonary pathology [n (%)] 23 (14.20) 15 (31.25) 0.007 2.75 (1.21-6.22)
Moderate/severe liver pathology [n (%)] 15 (9.26) 11 (22.92) 0.011 2.91 (1.14-7.43)
Gastrointestinal ulcer [n (%)] 16 (9.88) 7 (14.58) 0.359 1.56 (0.54-4.38)
Inflammatory bowel disease [n (%)] 4 (2.47) 1 (2.08) 1 0.84 (0.02-8.77)
Haematological pathology [n (%)] 2 (1.23) 4 (8.33) 0.025 7.27 (0.99-81.83)
Concomitant infections [n (%)] 44 (27.16) 16 (33.33) 0.405 1.34 (0.63-2.83)
Risk factors for CDAD in the past 2 months
Chemotherapy [n (%)] 7 (4.32) 7 (14.58) 0.020 3.78 (1.11-12.87)
Radiotherapy [n (%)] 5 (3.09) 2 (4.17) 0.660 1.37 (0.13-8.67)
Corticotherapy [n (%)] 9 (5.56) 6 (12.5) 0.115 2.43 (0.67-8.11)
Dialysis [n (%)] 6 (3.70) 1 (2.08) 1 0.55 (0.01-4.75)
Surgery [n (%)] 82 (50.62) 15 (31.25) 0.018 0.44 (0.21-0.92)
Gastro-intestinal/abdominal surgery [n (%)] 37 (22.84) 6 (12.5) 0.118 0.48 (0.17-1.30)
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Table 2 Risk factors for unfavourable outcome of CDAD (Continued)
Enteral feeding [n (%)] 1 (0.62) 3 (6.25) 0.038 10.73 (0.83-566.82)
Parenteral feeding [n (%)] 5 (3.09) 17 (35.42) <0.001 17.22 (5.47-62.96)
Prior antibiotic treatment [n (%)] 115 (70.99) 30 (62.50) 0.264 1.47 (0.71-3.04)
Intestinal motility inhibitors after CDAD onset 17 (10.49) 3 (6.25) 0.576 0.57 (0.10-2.10)
Proton pump inhibitors after CDAD onset [n (%)] 16 (9.88) 6 (12.5) 0.602 1.30 (0.39-3.78)
Other antacids after CDAD onset [n (%)] 45 (27.78) 20 (41.67) 0.067 1.86 (0.90-3.82)
Antibiotic use after CDAD diagnosis (other than
for CDAD) [n (%)]
15 (9.26) 17 (35.42) <0.001 5.37 (2.26-12.84)
Median no. days of antibiotherapy after onset of
episode (other than the treatment for CDAD)
0 (0–0) 0 (0–3) 0.017 1.09 (1.01-1.18)
Median no. antibiotics after onset of episode
(other than the treatment for CDAD) [no. (IQR)]
0 (0–0) 0 (0–1) 0.002 1.74 (1.21-2.50) 0.047 2.69 (1.01-7.17)
Treatment for CDAD
Metronidazole [n (%)] 36 (22.22) 6 (12.5) 0.139 0.50 (0.16-1.32)
Vancomycin [n (%)] 47 (29.01) 11 (22.92) 0.406 0.73 (0.32-1.63)
Vancomycin + Metronidazole [n (%)] 71 (43.83) 28 (58.33) 0.077 1.79 (0.89-3.63)
Rifaximin - α (alone or in combination) [n (%)] 8 (4.93) 1 (2.08) 0.687 0.41(0.01-3.20)
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2.692, 95% CI = 1.01 to 7.17, p = 0.047).
A second comparison aimed at the identification of
the risk factors for recurrence of symptoms induced by
CD. In our study, 42 patients (20.00%) were identified
with recurrence. While the univariate analysis associated
the number of days of hospitalization, leukocytosis over
16,000 cells/μl, hypoalbuminemia <3.5 g/dL, the ATLAS
Score and severe clinical form of recurrence risk, after
the multivariate logistic regression model, this associ-
ation remained only in terms of the number of days
of hospitalization (OR = 1.10, 95% CI = 1.03 to 1.16, p =
0.0015) (Table 3).Discussion
The high incidence identified in our study – 20.57/15.70
to 1,000 discharged patients in 2013/2014 or 17.73/14.04
to 10,000 patient-days - is explained by the endemicity
in some hospitals in Timisoara, released in late 2012,
and the fact that “Victor Babeş” Hospital is the only
one in our area that provides treatment in all sus-
pected or confirmed cases of this condition requiring
hospitalization. The incidence was significantly higher
in the age group over 60 years, but cases in young
patients were also reported (lowest reported age was
19 years).
In Romania, the ”Matei Bals” Institute in Bucharest
reported an increase in the number of infections with
this germ from 1.67 cases/month in 2010 and 2 cases/
month in 2011 to 60 cases/month in 2013, so that the
average rate of 11.67 new cases/month identified by us
between 2013–2014 is still lower [6,7].In Hungary, the incidence of nosocomial CDAD was
estimated at 1.2-2.8 to 10,000 patient-days during a 2011–
2012 [8]. The EUCLID study conducted in 20 European
countries, including 482 hospitals, shows a substantial
increase in the incidence from 4.1 in 2008 to 6.8 cases/
10,000 patient-days in 2013 [9]. In a Czech study pub-
lished in 2014, CDAD was 1/10,000 patient-days, with a
mortality rate of 22.4% [10].
Global fatality at 30 days varies between 9 and 38% (in
a 2012 review) and between 8 and 31% (in a 2014 review)
[11,12]. In our study, fatality at 30 days was 21.42% and
recurrence was observed in 20% of patients.
The link between antibiotic use and hospital acquired
CD infection has been supported by a number of epi-
demiological studies conducted since the 1990s. In hos-
pital settings, the main risk factor is represented by the
requirement for antibiotic treatments which, in the
absence of careful clinical monitoring and epidemiologic
surveillance, may become the source of ”serial” CDAD
cases. The repeated courses of antibiotics played a sig-
nificant part – excessive use of antibiotics is responsible
for the destruction of the normal intestinal microbial
flora, with the consecutive selection and development of
resistant strains of pathogens. In our study group, 145
patients (69.05%) received antibiotics before the onset of
enterocolitis, most of them received III-rd generation
cephalosporins, fluoroquinolones, carbapenems and β–
lactams associated with β-lactamase inhibitor.
Old age is identified as a risk factor for complica-
tions and death in many other articles [10,13-18]. In
our study, it maintained its risk factor status in the
multivariate analysis as well, but with values close to
the limit. The Charlson comorbidity index includes
Table 3 Risk factors for CDAD relapse
Variable Single episode Recurrence of
symptoms
Univariate analysis Multivariate analysis
(N = 168) (N = 42) p OR (95% CI) p OR (95% CI)
Demographic characteristics
Median age [years (IQR)] 67.5 (57–76) 74 (58–82) 0.266 1.01 (0.99-1.03)
Female gender [n (%)] 86 (51.19) 24 (57.14) 0.489 1.27 (0.61-2.66)
Urban area [n (%)] 111 (66.07) 35 (83.33) 0.029 0.39 (0.14-0.97)
Clinical and evolutive characteristics
Nosocomial infection with CD [n (%)] 164 (97.62) 40 (95.24) 0.344 2.05 (0.18-14.83)
Median hospitalization for CDAD [days (IQR)] 10 (7–13) 12 (8–17) 0.004 1.12 (1.05-1.19) 0.0015 1.10 (1.03-1.16)
Median no. of leukocytes [cells/μl (IQR)] 9615 (6930–13820) 12625 (7830–17230) 0.277 1.00 (1.00-1.001)
Leukocytosis ≥ 16000 cells/μl [n (%)] 29 (17.26) 15 (35.71) 0.008 2.66 (1.18-5.99)
Hypoalbuminemia <3.5 g/dl [n (%)] 127 (75.59) 39 (92.86) 0.014 4.2 (1.22-22.22)
Fever > 37.5°C [n (%)] 40 (23.81) 13 (30.95) 0.340 1.43 (0.64-3.20)
Median ATLAS Score (IQR) 2 (2–4) 4 (2–5) 0.004 1.27 (1.07-1.51)
Mild clinical form [n (%)] 7 (4.17) 0 (0) 0.349 0.00 (0.00-2.78)
Moderate clinical form [n (%)] 127 (75.59) 26 (61.90) 0.074 0.52 (0.24-1.14)
Severe clinical form [n (%)] 34 (20.24) 16 (38.09) 0.015 2.43 (1.10-5.33)
Comorbidities
Median Charlson comorbidity index score (IQR) 2.5 (1–4) 2.5 (1–4) 0.775 1.02 (0.88-1.18)
Median Charlson comorbidity Index score adjusted
for age (IQR)
5 (3–7) 5 (4–7) 0.446 1.04 (0.93-1.16)
Malignancy [n (%)] 34 (20.24) 10 (23.81) 0.611 1.23 (0.51-2.93)
Colorectal cancer [n (%)] 5 (2.98) 0 (0) 0.585 0.00 (0.00-4.40)
Diabetes mellitus [n (%)] 39 (23.21) 9 (21.43) 0.805 0.90(0.37-2.189
Renal disease [n (%)] 40 (23.81) 7 (16.67) 0.320 0.64 (0.24-1.65)
Chronic renal failure [n (%)] 29 (17.26) 6 (14.29) 0.643 0.8 (0.25-2.16)
Chronic heart disease [n (%)] 85 (50.59) 26 (61.90) 0.189 1.59 (0.75-3.36)
Peripheral vascular disease [n (%)] 30 (17.86) 10 (23.81) 0.379 1.44 (0.59-3.46)
Dementia [n (%)] 7 (4.17) 3 (7.14) 0.422 1.77 (0.28-8.17)
Cerebrovascular disease [n (%)] 42 (25) 13 (30.95) 0.432 1.34 (0.60-2.99)
Chronic pulmonary pathology [n (%)] 30 (17.86) 8 (19.05) 0.857 1.08 (0.41-2.75)
Moderate/severe liver pathology [n (%)] 19 (11.31) 7 (16.67) 0.345 1.57 (0.55-4.35)
Gastrointestinal ulcer [n (%)] 18 (10.71) 5 (11.90) 0.786 1.13 (0.31-3.42)
Inflammatory bowel disease [n (%)] 4 (2.38) 1 (2.38) 1 1 (0.02-10.46)
Haematological pathology [n (%)] 5 (2.98) 1 (2.38) 1 0.80 (0.02-7.40)
Concomitant infections [n (%)] 48 (28.57) 12 (28.57) 1 1 (0.44-2.24)
Risk factors for CDAD in the past 2 months
Chemotherapy [n (%)] 12 (7.14) 2 (4.76) 0.740 0.65 (0.07-3.11)
Radiotherapy [n (%)] 5 (2.98) 2 (4.76) 0.629 1.63 (0.15-10.38)
Corticotherapy [n (%)] 14 (8.33) 1 (2.38) 0.313 0.27 (0.01-1.87)
Dialysis [n (%)] 6 (3.57) 1 (2.38) 1 0.66 (0.01-5.67)
Surgery [n (%)] 78 (46.43) 19 (45.24) 0.889 0.95 (0.46-1.98)
Gastro-intestinal/abdominal surgery [n (%)] 36 (21.43) 7 (16.67) 0.493 0.73 (0.27-1.91)
Enteral feeding [n (%)] 4 (2.38) 0 (0) 0.586 0.00 (0.00-6.12)
Parenteral feeding [n (%)] 19 (11.31) 3 (7.14) 0.578 0.60 (0.11-2.21)
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Table 3 Risk factors for CDAD relapse (Continued)
Prior antibiotic treatment [n (%)] 120 (71.43) 25 (59.52) 0.135 1.70 (0.80-3.62)
Intestinal motility inhibitors after CDAD onset 15 (8.93) 5 (11.90) 0.560 1.38 (0.37-4.32)
Proton pump inhibitors after CDAD onset [n (%)] 21 (12.50) 1 (2.38) 0.086 0.17 (0.00-1.13)
Other antacids after CDAD onset [n (%)] 54 (32.14) 11 (26.19) 0.455 0.75 (0.33-1.69)
Antibiotics after CDAD diagnosis (other than the
treatment for CDAD) [n (%)]
23 (13.69) 9 (21.43) 0.212 1.72 (0.67-4.36)
Median no. days of antibiotherapy after onset of
episode (other than the treatment for CDAD)
0 (0–0) 0 (0–0) 0.834 1.00 (0.92-1.10)
Median no. antibiotics after onset of episode
(other than the treatment for CDAD) [no. (IQR)]
0 (0–0) 0 (0–0) 0.746 1.06 (0.73-1.55)
Treatment for CDAD
Metronidazole [n (%)] 37 (22.02) 5 (11.9) 0.142 0.48 (0.14-1.35)
Vancomycin [n (%)] 47 (27.98) 11 (26.19) 0.816 0.91 (0.39-2.08)
Vancomycin + Metronidazole [n (%)] 75 (44.64) 24 (57.14) 0.146 1.65 (0.79-3.46)
Rifaximin - α (alone or in combination) [n (%)] 7 (4.17) 2 (4.76) 1 1.15 (0.11-6.35)
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dicator to assess the risk of dying within 1 year. It is
associated with the unfavourable outcome of the
CDAD in an article from 2013, designed by the study
group of Clostridium difficile in Barcelona, along with
the age and continuation of the antibiotic treatment
after the onset of enterocolitis [3]. In our study, the multi-
variate analysis does not retain the comorbidity index
among the 30-day fatality risk factors, as we have seen in
other studies [19,20]. This result may shift clinicians’
attention from age and comorbidity (which are little modi-
fiable, if at all) to other extrinsic factors that can have a
positive influence on the patient's evolution. The ATLAS
score, predictive of poor outcome in our study (OR = 4.97,
95% CI = 2.12 to 11.66, p <0.001) included the following
variables: age > 60 years, body temperature > 37.5°C,
leukocytosis ≥ 16,000 cells/μl, hypoalbuminemia <3.5 g/dL
and administration of systemic antibiotics (other than
those for CDAD). Leukocytosis is incriminated not only in
Alexey Markelov's studies [15,21] but also in those of
Bhangu S. or Im G.Y. [17,22]. Hypoalbuminemia occurs as
a variable associated with increased risk of mortality in
several articles in recent years [10,17,21]. CDAD is trad-
itionally associated with the consumption of clindamycin,
III-rd generation cephalosporins and penicillins, and more
recently with fluoroquinolones [23]. In a study conducted
by Balihar Karela et al., high incidence was associated with
consumption of penicillin but negatively correlated with
the consumption of nitroimidazoles [10]. Continuing anti-
biotic administration after the onset of CDAD (other than
for the treatment of enterocolitis) is incriminated in the
study of Dolors Rodríguez-Pardo and his colleagues
(2013) but also in the one from 2009 of the team led by
Hu M.Y [3,24]. Our study identified, as a risk factor, the
number of antibiotics administered after CDAD onset,other than the treatment for enterocolitis. (OR = 2.692,
95% CI = 1.01 to 7.17, p = 0.047).
We have not found any direct association between
severe evolution and malignancy, but univariate analysis
of variables retains chemotherapy on the list of signifi-
cant risk factors.
In the literature, the increased risk of recurrence is
associated with the age, leukocytosis over 15,000 cells/μl,
continued treatment with proton pump inhibitors after
the onset of CDAD or antibiotics concomitant with
CDAD therapy, severe/fulminant clinical form and anti-
toxin A IgG <1.29 ELISA units [3,24].
The limitations of our study arise from the use of in-
sufficiently sensitive diagnostic tests, resulting in a high
percentage of false negative samples and, hence, the
probability of missing the unconfirmed cases. By repeat-
ing the test at 48–72 h in patients with suggestive symp-
toms and epidemiological context, we tried to reduce
the impact of the lower sensitive immunochromato-
graphic methods as much as possible. The fatality rate
could influence the analysis of recurrence risk factors.
Conclusions
Clostridium difficile is a public health problem that has
also emerged in Romania in the past three years. The
emergence of this infection means an increase in the
average duration of hospitalization and inpatient care
costs, an increased number of deaths, especially among
elderly patients, and compromising the effectiveness of
medical interventions performed in hospitals where out-
breaks of CDAD are evolving.
Our study identified the ATLAS score, age, and num-
ber of antibiotics after episode onset as predictors of an
unfavourable outcome, while the number of days of
hospitalization was associated with symptom recurrence.
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